Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: To provide a vehicle seatbelt capable of suppressing the reduction in the power holding of a buckle webbing, a vehicle seatbelt includes a buckle webbing and a buckle mounted at an end of the buckle webbing. The buckle webbing is provided with a webbing loop portion connected to the buckle. The vehicle seatbelt also includes an elastic holding band for holding the buckle webbing inside the seat by stretching the buckle webbing. In the webbing loop portion a band guide member is mounted. The elastic holding band passes through the band guide member and is routed to wrap around the webbing loop portion.

Abstract: To provide a vehicle seatbelt capable of suppressing the reduction in the power holding a buckle webbing, a vehicle seatbelt 1 includes a buckle webbing 4 and a buckle 5 mounted at an end of the buckle webbing 4. The buckle webbing 4 is provided with a webbing loop portion 9 formed in a loop shape as well as connected to the buckle 5. The vehicle seatbelt 1 also includes an elastic holding band 12 for holding the buckle webbing 4 inside the seat by stretching the buckle webbing 4. In the webbing loop portion 9, a band guide member 13 is mounted, through which the elastic holding band 12 passes. The elastic holding band 12 passes through the band guide member 13 as well as the elastic holding band 12 is routed to wrap the webbing loop portion 9 therewith from the outside of the loop of the webbing loop portion 9 operatively in associated with the band guide member 13.